{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:02:03Z","timestamp":1781665323312,"version":"3.54.5"},"reference-count":67,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AAG-G-00-99-00005"],"award-info":[{"award-number":["AAG-G-00-99-00005"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203919\/Z\/16\/Z"],"award-info":[{"award-number":["203919\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:p>\n                    The distribution of\n                    <jats:italic>N<\/jats:italic>\n                    -acetyltransferase 2 gene (\n                    <jats:italic>NAT2<\/jats:italic>\n                    ) polymorphisms varies considerably among different ethnic groups. Information on\n                    <jats:italic>NAT2<\/jats:italic>\n                    single-nucleotide polymorphisms in the South African population is limited. We investigated\n                    <jats:italic>NAT2<\/jats:italic>\n                    polymorphisms and their effect on isoniazid pharmacokinetics (PK) in Zulu black HIV-infected South Africans in Durban, South Africa. HIV-infected participants with culture-confirmed pulmonary tuberculosis (TB) were enrolled from two unrelated studies.\n                  <\/jats:p>","DOI":"10.1128\/aac.02376-19","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T05:51:45Z","timestamp":1579153905000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["<i>N<\/i>\n                    -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and\n                    <i>N<\/i>\n                    -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment"],"prefix":"10.1128","volume":"64","author":[{"given":"Thuli","family":"Mthiyane","sequence":"first","affiliation":[{"name":"South African Medical Research Council, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Millard","sequence":"additional","affiliation":[{"name":"Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Liverpool, United Kingdom"},{"name":"Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom"},{"name":"Africa Health Research Institute, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Adamson","sequence":"additional","affiliation":[{"name":"Africa Health Research Institute, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusentha","family":"Balakrishna","sequence":"additional","affiliation":[{"name":"South African Medical Research Council, Biostatistics Department, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Connolly","sequence":"additional","affiliation":[{"name":"South African Medical Research Council, Biostatistics Department, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Rustomjee","sequence":"additional","affiliation":[{"name":"South African Medical Research Council, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[{"name":"Lung Infection and Immunity Unit, Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Pym","sequence":"additional","affiliation":[{"name":"South African Medical Research Council, Durban, South Africa"},{"name":"Africa Health Research Institute, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Global tuberculosis report. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_2_5_2","first-page":"566","article-title":"Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans","volume":"235","author":"Lauterburg BH","year":"1985","unstructured":"Lauterburg BH, Smith CV, Todd EL, Mitchell JR. 1985. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 235:566\u2013570.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)88984-0"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/bf01086149"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977225part1602"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1733-1738.2005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5197.485"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.12.5237"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)38219-5"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.5.9154882"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/bf00210758"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32102"},{"key":"e_1_3_2_16_2","first-page":"256","article-title":"Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity","volume":"4","author":"Ohno M","year":"2000","unstructured":"Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J. 2000. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuber Lung Dis 4:256\u2013261.","journal-title":"Int J Tuber Lung Dis"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0377"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977223251"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1972.106.3.357"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-2-181"},{"key":"e_1_3_2_21_2","first-page":"97","article-title":"Evaluation of isoniazid-associated hepatitis by immunological tests","volume":"32","author":"Warrington RJ","year":"1978","unstructured":"Warrington RJ, Tse KS, Gorski BA, Schwenk R, Sehon AH. 1978. Evaluation of isoniazid-associated hepatitis by immunological tests. Clin Exp Immunol 32:97\u2013104.","journal-title":"Clin Exp Immunol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb00659.x"},{"key":"e_1_3_2_23_2","first-page":"508","article-title":"Enzymes and drug sensitivity. Acetylation polymorphisms","volume":"57","author":"Evans DA","year":"1964","unstructured":"Evans DA. 1964. Enzymes and drug sensitivity. Acetylation polymorphisms. Proc R Soc Med 57:508\u2013511.","journal-title":"Proc R Soc Med"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200411-1557OC"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9609132"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0305-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03931-14"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00749-10"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis353"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1429-9"},{"key":"e_1_3_2_31_2","first-page":"581","article-title":"Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity","volume":"57","author":"Cascorbi I","year":"1995","unstructured":"Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. 1995. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581\u2013592.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.124"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199406000-00003"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/10937400903158383"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21957"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2156-9-21"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/500614"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.34.9.758"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1968.tb48255.x"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.5.729"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.122"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/bf03256314"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/hgv.2014.14"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.9438"},{"key":"e_1_3_2_45_2","first-page":"1132","article-title":"Isoniazid acetylator status of black South African tuberculosis patients","volume":"50","author":"Bach PH","year":"1976","unstructured":"Bach PH, Higgins-Opitz SB, Bima B, Leary WP. 1976. Isoniazid acetylator status of black South African tuberculosis patients. S Afr Med J 50:1132\u20131134.","journal-title":"S Afr Med J"},{"key":"e_1_3_2_46_2","volume-title":"Pharmacogenetics of arylamine N-acetyltransferase genes in South African populations","author":"Werely CJ","year":"2012","unstructured":"Werely CJ. 2012. Pharmacogenetics of arylamine N-acetyltransferase genes in South African populations. Stellenbosch University, Stellenbosch, South Africa."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200003000-00009"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90168-X"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0222-8"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-008-0511-y"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199604000-00004"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2018-0166"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0361-090X(02)00010-7"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200301000-00008"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05526-11"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000232"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01754.x"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/00970002042006004"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0777-6"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225020-00005"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198409060-00003"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_1.S15"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb01496.x"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-15-61"},{"key":"e_1_3_2_65_2","volume-title":"Treatment of tuberculosis: guidelines","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. Treatment of tuberculosis: guidelines, 4th ed. World Health Organization, Geneva, Switzerland.","edition":"4"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01195-15"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1086\/379378"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1086\/319501"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02376-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02376-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:31:32Z","timestamp":1645468292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02376-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3,24]]}},"alternative-id":["10.1128\/AAC.02376-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02376-19","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/864454","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"2019-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02376-19"}}